| Literature DB >> 32507006 |
Joshua Decruz1, Sumanth Prabhakar1, Benjamin Tze Kiong Ding1, Remesh Kunnasegaran1.
Abstract
Background and purpose - The ongoing Coronavirus Disease-19 (COVID-19) pandemic has taken a toll on healthcare systems around the world. This has led to guidelines advising against elective procedures, which includes elective arthroplasty. Despite arthroplasty being an elective procedure, some arthroplasties are arguably essential, as pain or functional impairment maybe devastating for patients, especially during this difficult period. We describe our experience as the Division of Arthroplasty in the hospital at the epicenter of the COVID-19 pandemic in Singapore.Patients and methods - The number of COVID-19 cases reported both nationwide and at our institution from February 2020 to date were reviewed. We then collated the number of arthroplasties that we were able to cope with on a weekly basis and charted it against the number of new COVID-19 cases admitted to our institution and the prevalence of COVID-19 within the Singapore population.Results - During the COVID-19 pandemic period, a significant decrease in the volume of arthroplasties was seen. 47 arthroplasties were performed during the pandemic period from February to April, with a weekly average of 5 cases. This was a 74% reduction compared with our institutional baseline. The least number of surgeries were performed during early periods of the pandemic. This eventually rose to a maximum of 47% of our baseline numbers. Throughout this period, no cases of COVID-19 infection were reported amongst the orthopedic inpatients at our institution.Interpretation - During the early periods of the pandemic, careful planning was required to evaluate the pandemic situation and gauge our resources and manpower. Our study illustrates the number of arthroplasties that can potentially be done relative to the disease curve. This could serve as a guide to reinstating arthroplasty as the pandemic dies down. However, it is prudent to note that these situations are widely dynamic and frequent re-evaluation is required to secure patient and healthcare personnel safety, while ensuring appropriate care is delivered.Entities:
Mesh:
Year: 2020 PMID: 32507006 PMCID: PMC8023950 DOI: 10.1080/17453674.2020.1774138
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Figure 1.Weekly COVID-19 caseload at NCID/TTSH in comparison with cases nationwide.
Figure 2.Weekly comparison of total COVID-19 cases in Singapore (cumulative numbers), and the number of arthroplasties performed at TTSH.
Figure 3.Weekly comparison of number of new COVID-19 cases reported at TTSH/NCID and number of arthroplasties performed at TTSH.
Demographic data on 47 arthroplasties
| Demographic | mean (SD) | n |
| Female sex | 35 | |
| Age | 68 (8.1) | |
| 50–59 | 11 | |
| 60–69 | 13 | |
| 70–79 | 19 | |
| 80–89 | 4 | |
| BMI | 27 (5.5) | |
| 15–19 | 2 | |
| 20–24 | 15 | |
| 25–29 | 19 | |
| 30–34 | 6 | |
| 35–39 | 3 | |
| 40–44 | 1 | |
| 45–49 | 1 | |
| ASA Class: | ||
| 1 | 1 | |
| 2 | 32 | |
| 3 | 14 | |
| Operation performed | ||
| TKR | 32 | |
| THR | 5 | |
| UKA | 10 | |
| Indication | ||
| Osteoarthritis | 39 | |
| Rheumatoid arthritis | 2 | |
| Avascular necrosis | 4 | |
| Revision surgery | 2 | |
| Length of stay (days) | 4.7 (2.3) | |
| 29 | ||
| 5–10 | 16 | |
| 2 |
Management of TTSH Arthroplasty Division against the World Health Organization (WHO) pandemic phases
| WHO pandemic phase | Definition | Arthroplasty unit management goals | Arthroplasty caseload limit | Manpower contribution for pandemic | Elective cases selection criteria | |
| Human infection (transmission in close contacts) | Assessment of stockpile and resources | 100% | 0% | All cases | ||
| Small cluster (< 25 cases lasting < 2 weeks) | Consider postponing future cases that are high risk (ASA 3 and above) or less severe | 100% | 0% | All cases | ||
| Large cluster (25–50 cases over 2–4 weeks) usage | Minimize use of intensive care beds/blood products Limit stockpile and manpower Severe arthropathy with limited mobility | 50% | 25% | ASA 1 or 2 patients Unlikely to require intensive care/blood products | ||
| Widespread in general population | Preserve intensive care beds/blood products Stockpile for pandemic usage solely | 0% | 25–75% | Cancel all cases | ||
| Levels of infections have dropped below peak levels in most countries | Minimize use of intensive care beds/blood products Limit stockpile and manpower usage | 25% | 25% | Same as Phase 5 |